LM Advisors’s Inovio Pharmaceuticals INO Stock Holding History

LM Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$609	–	458
2023 Q4	$609	Buy	+100	New	+$494	﹤0.01%	709

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LM Advisors's INO Position: Q1 2024 in Review

LM Advisors sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 100 shares — an estimated $609 sold.

LM Advisors first reported a position in INO in Q4 2023 and held it in 1 quarter. The position peaked at $609 in Q4 2023. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

LM Advisors reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 100 Inovio Pharmaceuticals shares in Q1 2024, an estimated $609.
LM Advisors first reported a position in Inovio Pharmaceuticals in Q4 2023 and held it in 1 quarter.
LM Advisors's Inovio Pharmaceuticals position peaked at $609 in Q4 2023.
89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.